Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15341657 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL4119422 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL4119416 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL4119419 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL3103833 | 0.90 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL21409310 | 0.90 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL3103820 | 0.90 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL3103830 | 0.90 | DPP4 (0.52) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15848812 | 0.89 | DPP4 (0.42) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL17210364 | 0.83 | DPP4 (0.49) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.